Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company, has announced the granting of non-statutory stock options to a newly hired non-executive employee. The grant, made on September 3, 2024, covers 2,500 shares of common stock at an exercise price of $25.15 per share, matching the closing price on the Nasdaq Global Select Market that day.
The options were granted under the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, and approved by the compensation committee. In accordance with Nasdaq Listing Rule 5635(c)(4), this grant serves as a material inducement for the employee's acceptance of employment. The vesting schedule is set for one-third of the shares annually over three years, contingent on continuous service. The options will expire after ten years unless terminated earlier.
Anika Therapeutics (NASDAQ: ANIK), un'azienda globale impegnata nella preservazione delle articolazioni, ha annunciato l'assegnazione di opzioni su azioni non statutarie a un nuovo dipendente non esecutivo. L'assegnazione, effettuata il 3 settembre 2024, comprende 2.500 azioni ordinarie a un prezzo di esercizio di $25.15 per azione, corrispondente al prezzo di chiusura del Nasdaq Global Select Market di quel giorno.
Le opzioni sono state assegnate nell'ambito del Piano di Induzione Anika Therapeutics, Inc. 2021, come modificato, e approvato dal comitato per le compensazioni. In conformità con la Regola di Quotazione Nasdaq 5635(c)(4), questa assegnazione funge da induzione materiale per l'accettazione dell'impiego da parte del dipendente. Il programma di maturazione è fissato per un terzo delle azioni annualmente nel corso di tre anni, a condizione di un servizio continuativo. Le opzioni scadranno dopo dieci anni, salvo cessazione anticipata.
Anika Therapeutics (NASDAQ: ANIK), una empresa global de preservación articular, ha anunciado la concesión de opciones sobre acciones no estatutarias a un nuevo empleado no ejecutivo. La concesión, realizada el 3 de septiembre de 2024, abarca 2,500 acciones ordinarias a un precio de ejercicio de $25.15 por acción, que coincide con el precio de cierre en el Nasdaq Global Select Market ese día.
Las opciones fueron concedidas bajo el Plan de Inducción Anika Therapeutics, Inc. 2021, enmendado, y aprobado por el comité de compensación. De acuerdo con la Regla de Listado Nasdaq 5635(c)(4), esta concesión sirve como un inducimiento material para la aceptación del empleo por parte del empleado. El cronograma de adquisición se establece en un tercio de las acciones anualmente durante tres años, condicionado a un servicio continuo. Las opciones vencerán después de diez años, a menos que se terminen antes.
아니카 치료제(나스닥: ANIK), 글로벌 관절 보존 회사가 새로 고용된 비상임 직원에게 비법적 주식 옵션을 부여했다고 발표했습니다. 이 부여는 2024년 9월 3일에 이루어졌으며, 2,500주의 보통주가 $25.15의 행사 가격으로 제공되며, 이는 해당 날 나스닥 글로벌 셀렉트 마켓의 종가와 일치합니다.
옵션은 아니카 치료제, Inc. 2021 유도 계획에 따라 부여되었으며, 수정되어 보상위원회에서 승인되었습니다. 나스닥 상장 규칙 5635(c)(4)에 따라, 이번 부여는 직원이 고용을 수락하는데 있어 중요한 유인책으로 작용합니다. 행사 일정은 3년 동안 매년 1/3씩의 주식이 분할될 예정이며, 지속적인 근무에 따라 달라집니다. 옵션은 10년 후 만료되며, 조기 종료되지 않는 한 그대로 유지됩니다.
Anika Therapeutics (NASDAQ : ANIK), une entreprise mondiale de préservation des articulations, a annoncé l'attribution de options d'achat d'actions non statutaires à un nouvel employé non exécutif. L'attribution, faite le 3 septembre 2024, couvre 2 500 actions ordinaires à un prix d'exercice de 25,15 $ par action, correspondant au prix de clôture de ce jour sur le Nasdaq Global Select Market.
Les options ont été accordées dans le cadre du Plan d'incitation Anika Therapeutics, Inc. 2021, tel que modifié, et approuvé par le comité de rémunération. Conformément à la règle de cotation Nasdaq 5635(c)(4), cette attribution sert d'inducement matériel à l'acceptation de l'emploi par l'employé. Le calendrier d'acquisition est fixé à un tiers des actions chaque année sur trois ans, sous réserve d'un service continu. Les options expireront après dix ans, sauf résiliation anticipée.
Anika Therapeutics (NASDAQ: ANIK), ein global tätiges Unternehmen zur Erhaltung von Gelenken, hat die Gewährung von nicht gesetzlich vorgeschriebenen Aktienoptionen an einen neu eingestellten nicht-executiven Mitarbeiter bekannt gegeben. Die Gewährung, die am 3. September 2024 erfolgte, umfasst 2.500 Aktien zu einem Ausübungspreis von 25,15 $ pro Aktie, was dem Schlusskurs am Nasdaq Global Select Market an diesem Tag entspricht.
Die Optionen wurden im Rahmen des Anika Therapeutics, Inc. 2021 Anreizplans, in der geänderten Fassung, gewährt und vom Vergütungsausschuss genehmigt. Gemäß der Nasdaq-Listing-Regel 5635(c)(4) dient diese Gewährung als wesentlicher Anreiz für die Annahme der Anstellung durch den Mitarbeiter. Der Vesting-Zeitplan sieht vor, dass ein Drittel der Aktien jährlich über drei Jahre erworben wird, vorausgesetzt, es besteht ein kontinuierlicher Dienst. Die Optionen verfallen nach zehn Jahren, es sei denn, sie werden vorher beendet.
- Stock options granted as a material inducement for new employee, potentially attracting talent
- Vesting schedule of one-third annually over three years encourages employee retention
- None.
BEDFORD, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 3, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of
Of the shares covered by the Options, one-third will vest on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date.
Unless earlier terminated in accordance with their terms, the Options will expire on the tenth anniversary of the grant date and are otherwise subject to the terms and conditions of the equity award agreement approved by Anika. The Options were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, which was not subject to stockholder approval.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc.
For Investor Inquiries:
Anika Therapeutics, Inc.
Mark Namaroff, 781-457-9287
Vice President, Investor Relations, ESG and Corporate Communications
investorrelations@anika.com
FAQ
How many stock options did Anika Therapeutics (ANIK) grant on September 3, 2024?
What was the exercise price for the stock options granted by Anika Therapeutics (ANIK)?
What is the vesting schedule for the stock options granted by Anika Therapeutics (ANIK)?
Under which plan were the stock options granted by Anika Therapeutics (ANIK)?
